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Abstract
AIM: To evaluate pre-treatment factors associated 
with sustained virological response (SVR) in patients 
with hepatitis C virus (HCV) genotype 3 treated with 
peginterferon and ribavirin (RBV). 
METHODS: We retrospectively analyzed treatment 
naive, mono-infected HCV genotype 3 patients treated 
with peginterferon and RBV. Exclusion criteria included 
presence of other liver disease, alcohol consumption 
and African American or Asian ethnicity. The variables 
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collected and compared between patients who achieved 
an SVR and patients who did not were as follows: 
gender, age, fibrosis stage, diabetes, body mass index, 
steatosis, INFL3  polymorphism, pre-treatment HCV-
RNA, type of peginterferon, RBV dose and adherence. 
RESULTS: A total of 107 patients treated between 
June, 2004 and March, 2013 were included. Mean 
treatment duration was 25.1 (± 1.8) wk. Overall, 58% 
(62/107) of the patients achieved an SVR and 42% 
(45/107) did not. In the multivariate logistic regression 
analysis, pre-treatment HCV-RNA ≥ 600000 UI/mL 
(OR = 0.375, 95%CI: 0.153-0.919, P  = 0.032) and 
advanced fibrosis (OR = 0.278, 95%CI: 0.113-0.684, 
P  = 0.005) were significantly associated with low SVR 
rates. In patients with pre-treatment HCV-RNA ≥ 
600000 UI/mL and advanced fibrosis, the probability 
of achieving an SVR was 29% (95%CI: 13.1-45.2). 
In patients with pre-treatment HCV-RNA < 600000 
UI/mL and mild to moderate fibrosis, the probability of 
achieving an SVR was 81% (95%CI: 68.8-93.4).
CONCLUSION: In patients with HCV genotype 3 
infections the presence of advance fibrosis and high 
pre-treatment viral load might be associated with poor 
response to peginterferon plus RBV. These patients 
could benefit the most from new direct antiviral agents-
based regimes. 
Key words:Sustained virological response; Direct 
antiviral agents; Sofosbuvir; Cirrhosis; Viral load
© The Author(s) 2015. Published by Baishideng Publishing 
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Core tip: Our study evaluates pre-treatment factors 
associated with sustained virological response in 
patients with hepatitis C virus genotype 3 treated 
with peginterferon plus ribavirin. We identified a sub-
group of patients with high pre-treatment viral load 
and advanced fibrosis whose chance of achieving a 
sustained virological response is as low as 29%. We 
believe these patients should be prioritized to access 
new treatment strategies.  
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INTRODUCTION
Hepatitis C virus (HCV) is a major health problem 
affecting more than 180 million people worldwide[1]. It 
is estimated that at least 350000 HCV infected people 
die annually due to liver-related causes[2].
Six genotypes of HCV have been identified. In Latin 
America, genotype 1 is the most prevalent, followed 
by genotypes 2 and 3[3,4]. In some areas of this region 
the prevalence of HCV genotype 3 (HCV-3) is as high 
as 30%[3]. 
Traditionally, HCV-2 and HCV-3 have been grouped 
together as “easy to treat” genotypes. However we 
now know that sustained virological response (SVR) 
rates of HCV-3 patients treated with peginterferon plus 
ribavirin (RBV) are sub-optimal. The global SVR rates 
for HCV-3 patients treated with peginterferon plus RBV 
are around 65%-70%[5,6]. Since these data mainly 
arise from randomized trials, SVR rates are expected 
to be lower in real-life patients with adverse factors[7].
Several host and viral factors have an impact on 
the SVR rate of patients infected with HCV-3 treated 
with peginterferon plus RBV. Pre-treatment factors 
that have been proposed to have a negative impact on 
SVR are advanced fibrosis or cirrhosis, male gender, 
non-Caucasian race, high body weight, diabetes 
mellitus, and high pre-treatment HCV-RNA[7-12]. More 
recently, INFL3 (formerly IL28B) polymorphisms 
were evaluated, but a clear association between the 
favorable INFL3 genotypes and SVR could not be 
established[13-15]. 
A major limitation of the studies that assessed 
predictors of SVR in HCV-3 patients lies in the fact 
that they evaluated HCV-2 and HCV-3 together, and 
difficulties arise when trying to draw conclusions for 
HCV-3 individually.
By the end of 2013, sofosbuvir was approved for the 
treatment of chronic HCV-3, being the standard of care 
in a minority of countries at the moment this manuscript 
was submitted. However, in regions like Latin America 
and Middle East/Africa, payer-related barriers were 
reported[16], which might hamper adequate treatment 
delivery. 
When new treatments become globally available, 
a careful selection of candidates will be mandatory, 
particularly for cost-related reasons. Therefore, it 
will be necessary to identify patients at higher risk of 
fibrosis progression and treatment failure to current 
therapies. 
Thus, we decided to conduct this study that eva-
luates pre-treatment variables associated with SVR in 
patients with chronic HCV-3 treated with peginterferon 
plus RBV.
MATERIALS AND METHODS
This is a retrospective multicenter study performed in 
7 Liver Units from Argentina. 
The centers involved in the study were, Hospital 
Italiano from Buenos Aires, Hospital R. Rossi from La 
Plata, Hospital F. J. Muñiz, Centro de Educación Médica 
e Investigaciones Clínicas Norberto Quirno (CEMIC), 
Hospital Universitario Austral, Sanatorio Parque from 
Rosario, and the HEPATOSUR Group representing the 
Patagonia.
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The survey was discussed by all the participating 
centers. The local institutional review board of each 
center approved the study. The study was conducted 
according to the principles of the Declaration of Helsinki.
Patients included in this study were aged ≥ 18 
years and received their first treatment with pegin-
terferon plus RBV for chronic hepatitis C genotype 3. 
Patients received weekly peginterferon alfa-2a 180 
μg or peginterferon alfa-2b 1.5 μg/kg of body weight. 
Ribavirin dose could be either fixed (800 mg/d) or 
adjusted to weight (1000 mg/d in patients ≤ 75 kg; 
1200 mg/d in patients > 75 kg).
Exclusion criteria included alcohol intake greater 
than 20 g/d, history of organ transplantation, creatinine 
clearance < 50 mL/min, co-infection with hepatitis B 
virus or human immunodeficiency virus and African 
American or Asian ethnicity. Patients were also excluded 
if they presented evidence of other liver disease, such 
as autoimmune hepatitis, primary biliary cirrhosis, 
sclerosing cholangitis, Wilson’s disease or alfa-1-
antitrypsin deficiency.
Each center provided detailed information of 
patients included in the study. Patient management and 
treatment candidacy were determined in each center. 
All data records were checked for missing values and 
inconsistencies, queries were sent to all participating 
institutions, and corrections were made at the data 
coordinating center, namely Hospital Italiano.
Efficacy assessment
Pre-treatment and follow-up blood samples were 
collected for virologic testing in each participating 
center. Serum HCV-RNA was either qualitatively or 
quantitatively evaluated. 
The primary end-point was SVR, defined as an 
undetectable serum HCV-RNA at 24 wk after the end 
of treatment. Rapid virological response was defined 
as an undetectable HCV-RNA by treatment week four. 
Virologic relapse was defined as a detectable HCV-RNA 
during follow-up in patients who had had undetectable 
HCV-RNA at the end of treatment. Those patients who 
never achieved a negative on-treatment HCV-RNA 
were classified as non-responders. 
Pre-treatment characteristics 
The variables that were collected and compared 
between patients who achieved an SVR and patients 
who did not were as follows: gender, age, fibrosis 
stage, diabetes, body mass index (BMI), steatosis, 
INFL3 polymorphism, pre-treatment HCV-RNA, type of 
peginterferon, RBV dose and adherence.
For the purpose of this study, high HCV-RNA was 
defined as ≥ 600000 UI/mL.
Fibrosis grade was staged either by biopsy or 
Transient Elastography (Fibroscan®). In patients without 
fibrosis evaluation, the aspartate aminotransferase 
to Platelet Ration Index (APRI) was calculated[17]. 
Patients were divided into two groups: patients with 
mild to moderate fibrosis, including patients without 
fibrosis and patients with up to METAVIR F2 fibrosis; 
and patients with advanced fibrosis, including patients 
with METAFIR F3 and cirrhosis[18]. Patients with clinical 
or endoscopic findings of cirrhosis were included in the 
advanced fibrosis group.
The presence of steatosis was evaluated either by 
ultrasound or histology. 
Since most patients did not have data regarding 
INFL3 polymorphism, they were contacted and invited 
to participate in this study in order to determine the 
genotype. Patients signed an informed consent before 
INFL3 genotyping. Genomic DNA was extracted from 
oral swabs using QIAamp DNA Blood Mini Kit (QIAGEN, 
GmbH, Hilden, Germany) following the manufacturer’s 
protocol.
SNP rs12979860 (INFL3) was PCR-amplified from 
isolated genomic DNA with standard Taq polymerase 
(Inbio-Highway, Tandil, Argentina)[19]. The PCR-amplified 
fragments were bi-directionally sequenced using Big-
Dye Termination chemistry system (Applied Biosystems, 
Life Technologies Corp., Foster City, CA, United States). 
The sequencing chromatogram was analyzed by using 
the BioEdit Sequence Alignment Editor version 7.1.3.0 
in order to discriminate between homozygotes and 
heterozygotes. Patients were grouped as INFL3 CC and 
INFL3 non-CC (including patients with INFL3 TT and 
CT).
Sample size calculation
In order to generate a predictive model including 
four variables, at least 40 patients without SVR had 
to be included. Assuming an SVR rate of 65%-70% 
in patients with HCV-3 treated with peginterferon 
plus RBV, between 100 and 110 patients had to be 
included[5,6]. 
Statistical analysis
We presented data as percentages or medians and 
interquartile ranges. We evaluated the association 
of pre-treatment characteristics with SVR using the 
Mann-Whitney test for continuous variables and the χ 2 
test for categorical variables.
In order to identify independent predictors of SVR 
we used a logistic regression model for the variables 
that showed a level of significance lower than 0.1 in 
the univariate analysis. We compared different models 
by estimating the area under the receiver operating 
characteristic curve (ROC) as a measure of predictive 
accuracy. We chose the model with the greatest 
area under the ROC and we presented the estimated 
probabilities predicted by the regression model with 
their 95% confidence interval (95%CI). Tests were 
two-sided and significance was accepted at P < 0.05. 
Statistical analysis was performed using software 
SPSS, version 17.0 (Chicago, IL).
RESULTS
Table 1 provides an overview of the patients’ char-
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logistic regression analysis and only high HCV-RNA 
(OR = 0.375, 95%CI: 0.153-0.919, P = 0.032) and 
advanced fibrosis (OR = 0.278, 95%CI: 0.113-0.684, 
P = 0.005) had a statistically significant negative 
association with SVR. 
The SVR rate was estimated according to the 
fibrosis grade and to the pre-treatment HCV-RNA. In 
patients with low pre-treatment HCV-RNA and mild 
to moderate fibrosis, the probability of achieving an 
SVR was 81% (95%CI: 68.8-93.4). In patients with 
high baseline HCV-RNA and advanced fibrosis, the 
probability of achieving an SVR was 29% (95%CI: 
13.1-45.2) (Table 3)
DISCUSSION
In the present study, we assessed pre-treatment 
predictors of SVR in patients infected with HCV-3 
who were treated with peginterferon and RBV. We 
identified high HCV-RNA and advanced fibrosis to be 
independently associated with treatment failure. 
Advanced fibrosis or cirrhosis have consistently 
been associated with lower rates of SVR in patients with 
HCV-3 treated with peginterferon plus RBV[9-11,20]. The 
chances of achieving an SVR after a 24-wk treatment 
acteristics. A total of 122 HCV-3 patients treated with 
peginterferon plus RBV patients were identified. Fifteen 
were excluded because of missing data, whereas 
107 were included (Figure 1). Patients were treated 
between June/2004 and March/2013. The mean 
age at treatment was 47.5 (± 8.8) years, and 68% 
(73/107) of the patients were male. In 93% (103/107) 
of the patients, a pre-treatment serum sample was 
collected. Of those patients, 55% (57/103) had high 
HCV-RNA. Pre-treatment fibrosis could be determined 
in 97% (104/107) of the patients, either by biopsy 
(62%), Fibroscan® (26%) or by a combination of 
clinical or endoscopic features and the APRI score 
(12%). Of these patients, 40% (41/104) had advanced 
fibrosis. Steatosis and a BMI > 27 were reported in 
48% (51/107) and 54% (58/107) of the patients, 
respectively. Data regarding INFL3 polymorphism was 
available in 60% (64/107) of the patients, of whom 
28% (18/64) were CC. 
Mean treatment durations was 25.1 (± 1.8) wk. Fix 
dose RBV was prescribed in 64% (68/107) patients, 
while the remaining ones received a weight-adjusted 
approach. More than 80% of the peginterferon and 
RBV planned doses were received by 94% (101/107) 
of the patients.
Virologic response
Overall, 58% (62/107) of the patients achieved an 
SVR. Of the 45 patients who did not achieve an SVR, 
71% (32/45) were relapsers and 9% (4/45) were non-
responders. In 20% (9/45) of the cases, the type of 
treatment failure was not possible to characterize due 
to lack of precise viral kinetic information (Figure 1). 
In the univariate analysis, SVR rate was significantly 
lower in patients with high baseline HCV-RNA (OR = 
0.330, 95%CI: 0.145-0.755, P = 0.009), advanced 
fibrosis (OR = 0.274, 95%CI: 0.145-0.755, P = 0.001) 
and BMI > 27 (OR = 0.422, 95%CI: 0.149-0.892, P = 
0.033) (Table 2).
These variables were included in the multivariate 
Table 1  Characteristics of the study population  n  (%)
Characteristic Patients
(n  = 107)
Age, yr (mean ± SD)1 47.5 (± 8.8)
Gender
   Male 68.2 (7)
   Female 1.8 (4)
INFL3 polymorphism2
   CT 56.2 (6)
   CC 28.1 (18)
   TT 15.7 (10)
Pre treatment HCV-RNA
   < 600000 UI/mL 44.7 (46)
   ≥ 6000000 UI/mL 55. (57)
Pre treatment elevated ALT4 88.5 (92)
Fibrosis5
   Mild to moderate6 59.8 (61)
   Advanced7 40.2 (41)
Steatosis 47.6 (51)
BMI (kg/m2) > 27 54.2 (58)
Diabetes 5.6 (6)
Type of peginterferon 
   alfa 2a 75.7 (81)
   alfa 2b 24. (26)
RBV dose 
   Fix8 6.6 (68)
   Weight-Based9 6.4 (9)
80/80/80 adherence10  94.4 (101)
1Available for 105 patients; 2Available for 64 patients; Available for 10 
patients; 4Available for 104 patients; 5Available for 102 patients; 6Mild to 
moderate fibrosis includes patients without fibrosis and patients with 
up to METAVIR F2 fibrosis; 7Advanced fibrosis includes patients with 
METAFIR F and cirrhosis; 8800 mg/d; 91000 mg/d in patients ≤ 75 kg 
weight, 1200 mg/d in patients > 75 kg weight; 10Patients received at least 
80% of the peginterferon and RBV doses, and completed at least 80% of 
the expected treatment duration. ALT: Alanino aminotransferase; HCV: 
Hepatitis C virus; RBV: Ribavirin; BMI: Body mass index.
122 HCV-3 infected patients 
treated with peginterferon plus RBV
15 patients excluded 
because of missing data
107 patients included
 62 (58%) patients 
achieved SVR
45 (42%) patients 
did not achieve SVR
32 (71%) patients 
were relapsers
4 (9%) patients were 
non-responders
9 (20%) patients not 
possible to determine
Figure 1  Inclusion, exclusion and outcome of patients. HCV: Hepatitis C 
virus; RBV: Ribavirin; SVR: Sustained virological response.
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for these patients are 49%-57%[21-23]. Besides, it is 
estimated that the likelihood of achieving an SVR is 
reduced by 59% in comparison with patients with lower 
fibrosis grades[20]. The impact of the pre-treatment 
HCV-RNA on SVR is more difficult to determine, since 
different cut-off points were selected in prior studies 
(400.000-800.000 IU/mL). Even though it has not 
been consistently associated with lower SVR rates, 
HCV-3 patients with high pre-treatment viral load do 
have lower rapid virological response rates[24]. 
In our study, we found that by combining baseline 
HCV-RNA and fibrosis stage, SVR rates could be 
accurately predicted. In patients with low HCV-RNA, 
and without advanced fibrosis, the SVR rate was 81%. 
On the contrary, in patients with high baseline HCV-
RNA and advanced fibrosis, the SVR rate was 29%. 
Other variables that were assessed in our study 
included age, gender, INFL3 polymorphism, steatosis, 
adherence, RBV dose, type of peginterferon, diabetes 
and BMI. None of these were associated with SVR. 
Steatosis is known to be more frequent in patients 
infected with HCV-3 than in other genotypes[25,26]. In our 
series, 48% of the patients presented steatosis, which 
was diagnosed either by biopsy or by ultrasonography. 
Even though HCV-3 is known to cause steatosis through 
specific viral mechanisms, in our study, 58% of the 
patients had a BMI > 27, reflecting an overweight 
population. In line with our results, most studies 
reported no impact of steatosis on SVR for patients with 
HCV-3[27,28]. Although the BMI was previously reported 
to have an impact on SVR[8], prior studies proposed 
different cut-off points and results were discordant. We 
selected a cut-off point of 27, and no association with 
SVR was found. Even though diabetes is associated with 
higher relapse rates in HCV G3 patients[20], we did not 
find this association, probably due to the low number of 
patients with diabetes that were included in the study.
INFL3 polymorphisms were more recently evaluated 
in patients with HCV-3 treated with peginterferon plus 
RBV. Putting together all the available information, it 
seems that INFL3-CC is not globally associated with 
SVR in HCV-3 patients. Nevertheless, it does predict 
SVR in the sub-group of patients who do not achieve 
a rapid virological response[13,15]. We did not find an 
association between INFL3-CC and SVR. 
No differences in the SVR rates were found in 
patients who received fixed-dose or weight-adjusted 
RBV. This was an expected finding, since mean 
treatment duration was 25.7 (± 1.8) wk, and RBV dose 
does have an impact on SVR when treatment duration 
is reduced, but not for the 24-wk regimen[21].
In order to evaluate treatment adherence we used 
the 80/80/80 rule. Overall, 94% of the patients were 
adherent. No differences were found in SVR rates 
between patients who were adherent and patients 
who were not. This was most likely due to the low 
proportion of patients who were non-compliant.
Until the end of 2013, the only treatment for HCV-3 
was peginterferon plus RBV. At that time, sofosbuvir-
based regimens were approved and released. With this 
new approach, more than 90% of the HCV-3 treatment-
naïve patients achieve an SVR, regardless of the fibrosis 
stage[29,30]. When this manuscript was submitted for its 
publication, sofosbuvir was only approved and available 
in a minority of countries. Numerous barriers related to 
Table 2  Association between pre-treatment characteristics and sustained virological response - Univariate 
Analyses  n  (%)
SVR (n  = 62) No-SVR (n  = 45) OR CI P
Age, yr (mean ± SD)1     47.8 (± 9.1)     47.1 (± 8.)       1 0.965-1.055 0.696
Male 61. (8) 77.8 (5) 0.425 0.190-1.079 0.09
INFL3 polymorphism CC2 1.4 (11)               24.1 (7)       1.44 0.475-4.72 0.585
HCV-RNA ≥ 600000 UI/mL 44.1 (26) 70.5 (1)       0. 0.145-0.755 0.009
Pre treatment elevated ALT4 86.7 (52) 90.9 (40)       0.65 0.18-2.12 0.55
Advanced fibrosis5,6 26.7 (16) 59.5 (25) 0.247 0.107-0.57 0.001
Steatosis 46.8 (29) 48.9 (22) 0.919 0.426-1.981 0.847
BMI (kg/m2) > 27 46.8 (29) 64.4 (29) 0.422 0.149-0.892 0.0
Diabetes    2 (1)  11 (5) 0.11 0.015-1.165        0.08
Peginterferon alfa 2a 75.8 (47) 75.6 (4) 0.986 0.40-2.41        1
RBV Fix-Dose7 64.5 (40) 62.2 (28) 1.104 0.498-2.447 0.841
80/80/80 adherence8 95.2 (59) 9. (42)       0.75 0.11-2.552 0.919
1vailable for 105 patients;  2Available for 64 patients; Available for 10 patients; 4Available for 104 patients; 5Advanced fibrosis 
includes patients with METAFIR F and cirrhosis; 6Available for 102 patients; 7800 mg/d; 8Patients received at least 80% of the 
peginterferon and RBV doses, and completed at least 80% of the expected treatment duration. ALT: Alanino aminotransferase; 
HCV: Hepatitis C virus; RBV: Ribavirin; BMI: Body mass index; SVR: Sustained virological response.
Table 3  Probability of sustained virological response 




Advanced fibrosis1 Probability (%) 95%CI
No No 81.1 68.8-9.4
Yes No 62.2 46.6-77.8
No Yes 51.8 1.-72.
Yes Yes 29.2 1.1-45.2
1Advanced fibrosis includes patients with METAFIR F3 and cirrhosis. HCV: 
Hepatitis C virus.
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patient, provider, government and payers are known 
to affect HCV treatment accessibility[31]. In developing 
countries, treatment-related costs constitute a major 
concern. In fact, in some Latin American countries, 
after more than three years of the release of Boceprevir 
and Telaprevir for the treatments of HCV genotype 1, 
accessibility is still limited.
In our study, we identified a sub-group of HCV-3 
infected patients with very low chances of achieving 
an SVR after treatment peginterferon plus RBV. These 
patients with high baseline HCV-RNA and advanced 
fibrosis are in urgent need for new therapeutic 
approaches and should be prioritized when sofosbuvir 
or other antivirals become available. A similar approach 
was recently proposed to identify a sub-group of 
patients infected with HCV genotype 1 who might 
benefit from peginterferon plus RBV therapy[32].
Owing to its retrospective nature, our study has 
several limitations. First, since patients were not 
consecutive, selection bias is possible, and therefore 
the SVR rate of our population cannot be extrapolated 
to the general population. Second, on-treatment 
virologic kinetics was not evaluated. Rapid virological 
response is probably the most important predictor of 
SVR across all genotypes[24]. A major limitation of rapid 
virological response to predict SVR, lies in the fact 
that being an on-treatment variable, it is not useful to 
determine treatment candidacy. Third, even though 
the number of patients included is small, it adequately 
represents the sample size estimated to provide the 
specific power. Finally, although differences regarding 
treatment protocols between the participating centers 
might have existed, treatment duration and adherence 
were globally homogeneous.
In conclusion, our study identified a sub-group of 
patients with chronic HCV-3 with high baseline viral 
load and advanced fibrosis whose chances of achieving 
an SVR with peginterferon plus RBV were poor. These 




Hepatitis C virus (HCV) is a major health problem affecting more than 180 
million people worldwide. It is estimated that at least 350000 HCV infected 
people die annually due to liver-related causes.
Research frontiers
Several host and viral factors have an impact on the sustained virological 
response (SVR) rate of patients infected with HCV genotype 3 (HCV-3) treated 
with peginterferon plus ribavirin (RBV). Pre-treatment factors that have been 
proposed to have a negative impact on SVR are advanced fibrosis or cirrhosis, 
male gender, non-Caucasian race, high body weight, diabetes mellitus, 
and high pre-treatment HCV-RNA. More recently, INFL3 (formerly IL28B) 
polymorphisms were evaluated, but a clear association between the favorable 
INFL3 genotypes and SVR could not be established. A major limitation of the 
studies that assessed predictors of SVR in HCV-3 patients lies in the fact that 
they evaluated HCV-2 and HCV-3 together, and difficulties arise when trying to 
draw conclusions for HCV-3 individually.
Innovations and breakthroughs
This study was designed to evaluate pre-treatment variables associated with 
SVR particularly for patients with chronic HCV-3 treated with peginterferon plus 
RBV. 
Applications
In the authors’ study, they identified a sub-group of HCV-3 infected patients 
with very low chances of achieving an SVR after treatment peginterferon plus 
RBV. In patients with both high baseline HCV-RNA and advanced fibrosis, the 
probability of achieving an SVR was 29%. We believe that these patients are 
in urgent need for new therapeutic approaches and should be prioritized when 
sofosbuvir or other antivirals become available.
Terminology
Genotype refers to the genetic relatedness of the different HCV species. Six 
genotypes of HCV have been well characterized. Fibrosis is a process in which 
scarring occurs in the liver, ultimately leading to cirrhosis, which is the greatest 
degree of fibrosis. Sustained virological response means viral eradication or 
cure.
Peer-review
This study was intended to find some factors associated with SVR in patients 
with HCV-3 treated with peginterferon and ribavirin. Both high viral load and 
advanced fibrosis were concluded to be associated with low SVR rates. The 
authors think this manuscript is well written and suitable for publication in World 
Journal of Hepatology.
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